{"resourceType":"EvidenceVariable","id":"example-alive-independent-90day","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \u003cp\u003e\n        \u0026quot;Alive and not functionally dependent at 90 days\u0026quot; is an outcome used in expressing what an Evidence is about.\n      \u003c/p\u003e\n\t\u003c/div\u003e"},"title":"Alive and not functionally dependent at 90 days","status":"draft","actual":false,"characteristicCombination":"intersection","characteristic":[{"description":"not functionally dependent at 90 days","definitionCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"718705001","display":"Functionally dependent (finding)"}]},"exclude":true,"timeFromStart":{"quantity":{"value":90,"unit":"day","system":"http://unitsofmeasure.org","code":"d"}}},{"description":"alive at 90 days","definitionCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"419099009","display":"Dead (finding)"}]},"exclude":true,"timeFromStart":{"quantity":{"value":90,"unit":"day","system":"http://unitsofmeasure.org","code":"d"}}}],"handling":"dichotomous"}
{"resourceType":"EvidenceVariable","id":"example-alteplase-for-stroke","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \u003cp\u003e\n        \u0026quot;Alteplase for Stroke\u0026quot; is an exposure concept with a detailed dosing instruction that may be used in expressing what an Evidence is about.\n      \u003c/p\u003e\n\t\u003c/div\u003e"},"title":"Alteplase for Stroke","status":"draft","actual":true,"characteristic":[{"description":"IV alteplase 0.9 mg/kg (maximum 90 mg) as 10% of dose over 1 minute and 90% over 1 hour","definitionCanonical":"http://example.org/fhir/ActivityDefinition/example-alteplase-dosing"}]}
{"resourceType":"EvidenceVariable","id":"example-dead-or-dependent-90day","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \u003cp\u003e\n        \u0026quot;Dead or functionally dependent at 90 days\u0026quot; is an outcome used in expressing what an Evidence is about.\n      \u003c/p\u003e\n\t\u003c/div\u003e"},"title":"Dead or functionally dependent at 90 days","status":"draft","actual":false,"characteristicCombination":"union","characteristic":[{"description":"functionally dependent at 90 days","definitionCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"718705001","display":"Functionally dependent (finding)"}]},"timeFromStart":{"quantity":{"value":90,"unit":"day","system":"http://unitsofmeasure.org","code":"d"}}},{"description":"dead at 90 days","definitionCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"419099009","display":"Dead (finding)"}]},"timeFromStart":{"quantity":{"value":90,"unit":"day","system":"http://unitsofmeasure.org","code":"d"}}}],"handling":"dichotomous"}
{"resourceType":"EvidenceVariable","id":"example-fatal-ICH-in-7-days","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \u003cp\u003e\n        \u0026quot;Fatal Intracranial Hemorrhage Within Seven Days\u0026quot; is an outcome used in expressing what an Evidence is about.\n      \u003c/p\u003e\n\t\u003c/div\u003e"},"title":"Fatal Intracranial Hemorrhage Within Seven Days","status":"draft","note":[{"text":"Death must be due to intracranial hemorrhage"}],"actual":true,"characteristicCombination":"intersection","characteristic":[{"description":"intracranial hemorrhage within 7 days","definitionCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"1386000","display":"Intracranial hemorrhage (disorder)"}]},"timeFromStart":{"description":"within 7 days","range":{"low":{"value":0,"unit":"day","system":"http://unitsofmeasure.org","code":"d"},"high":{"value":7,"unit":"day","system":"http://unitsofmeasure.org","code":"d"}}}},{"description":"death within 7 days","definitionCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"419620001","display":"Death (event)"}]},"timeFromStart":{"description":"within 7 days","range":{"low":{"value":0,"unit":"day","system":"http://unitsofmeasure.org","code":"d"},"high":{"value":7,"unit":"day","system":"http://unitsofmeasure.org","code":"d"}}}}],"handling":"dichotomous"}
{"resourceType":"EvidenceVariable","id":"example-mRS0-2-at-90days","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \u003cp\u003e\n        \u0026quot;mRS 0-2 at 90 days\u0026quot; is an outcome, defined by a CQL expression, used in expressing what an Evidence is about.\n      \u003c/p\u003e\n\t\u003c/div\u003e"},"title":"Modified Rankin Scale score 0-2 at 90 days after treatment","status":"draft","actual":true,"characteristic":[{"description":"mRS 0-2 at 90 days","definitionExpression":{"description":"mRS 0-2","language":"text/cql","expression":"[\"Observation\": code in \"75859-9|LOINC\"] mRS where mRS.value between 0 and 2"},"timeFromStart":{"quantity":{"value":90,"unit":"day","system":"http://unitsofmeasure.org","code":"d"}}}],"handling":"dichotomous"}
{"resourceType":"EvidenceVariable","id":"example-mRS3-6-at-90days","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \u003cp\u003e\n        \u0026quot;mRS 3-6 at 90 days\u0026quot; is an outcome, defined by a CQL expression, used in expressing what an Evidence is about.\n      \u003c/p\u003e\n\t\u003c/div\u003e"},"title":"Modified Rankin Scale score 3-6 at 90 days after treatment","status":"draft","actual":true,"characteristic":[{"description":"mRS 3-6 at 90 days","definitionExpression":{"description":"mRS 3-6","language":"text/cql","expression":"[\"Observation\": code in \"75859-9|LOINC\"] mRS where mRS.value between 3 and 6"},"timeFromStart":{"quantity":{"value":90,"unit":"day","system":"http://unitsofmeasure.org","code":"d"}}}],"handling":"dichotomous"}
{"resourceType":"EvidenceVariable","id":"example-no-alteplase","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \u003cp\u003e\n        \u0026quot;No alteplase\u0026quot; is an intended exposure concept that may be used in expressing what an Evidence is about.\n      \u003c/p\u003e\n\t\u003c/div\u003e"},"title":"no alteplase","status":"draft","actual":false,"characteristic":[{"description":"no alteplase","definitionCodeableConcept":{"coding":[{"system":"http://www.nlm.nih.gov/research/umls/rxnorm","code":"8410","display":"alteplase"}]},"exclude":true}]}
{"resourceType":"EvidenceVariable","id":"example-placebo","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n\t\t\u003cp\u003e\n\t\t\tPlacebo is a specific exposure that may be used in expressing what an Evidence is about.\n\t\t\u003c/p\u003e\n\t\u003c/div\u003e"},"title":"placebo","status":"draft","actual":true,"characteristic":[{"description":"placebo","definitionCodeableConcept":{"coding":[{"system":"http://snomed.info/sct","code":"182886004","display":"Placebo given (situation)"}]}}]}
{"resourceType":"EvidenceVariable","id":"example-Stroke-Thrombolysis-Trialists-2014-2016-IPD-MA-Cohort","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \u003cp\u003e\n        Stroke Thrombolysis Trialists’ Collaborators Group collection used for individual patient data meta-analysis\n      \u003c/p\u003e\n\t\u003c/div\u003e"},"name":"Stroke Thrombolysis Trialists’ 2014-2016 IPD-MA Cohort","title":"Stroke Thrombolysis Trialists’ Collaborators Group collection used for individual patient data meta-analysis","status":"draft","relatedArtifact":[{"type":"citation","label":"Emberson 2014","display":"Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.","citation":"Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al;Stroke Thrombolysis Trialists\u0027 Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014 Nov 29;384(9958):1929-35 PMID 25106063","url":"https://doi.org/10.1016/S0140-6736(14)60584-5"},{"type":"citation","label":"Lees 2016","display":"Figure 2 Lees 2016","citation":"Lees KR, Emberson J, Blackwell L, Bluhmki E, Davis SM, Donnan GA, et al; Stroke Thrombolysis Trialists’ Collaborators Group. Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials. Stroke. 2016;47:2373-2379. PMID 27507856","url":"https://doi.org/10.1161/STROKEAHA.116.013644"}],"actual":true,"characteristicCombination":"union","characteristic":[{"definitionReference":{"reference":"Group/ECASSIII-Trial-Cohort","type":"Group","display":"ECASS III Trial Cohort"}},{"definitionReference":{"reference":"Group/IST3-Trial-Cohort","type":"Group","display":"IST3 Trial Cohort"}},{"definitionReference":{"reference":"Group/ECASS-Trial-Cohort","type":"Group","display":"ECASS Trial Cohort"}},{"definitionReference":{"reference":"Group/ECASSII-Trial-Cohort","type":"Group","display":"ECASSII Trial Cohort"}},{"definitionReference":{"reference":"Group/EPITHET-Trial-Cohort","type":"Group","display":"EPITHET Trial Cohort"}},{"definitionReference":{"reference":"Group/ATLANTIS-Trial-Cohort","type":"Group","display":"ATLANTIS Trial Cohort"}},{"definitionReference":{"reference":"Group/NINDS-Trial-Cohort","type":"Group","display":"NINDS Trial Cohort"}}]}
{"resourceType":"EvidenceVariable","id":"example-Wardlaw2014Analysis1.16.3EvidenceSet","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\n      \u003cp\u003e\n        \u0026quot;Wardlaw 2014 Analysis 1.16.3 Evidence set\u0026quot; is a grouping of six Evidence results used in a meta-analysis.\n      \u003c/p\u003e\n\t\u003c/div\u003e"},"name":"Wardlaw 2014 Analysis 1.16.3 Evidence set","title":"Wardlaw 2014 Analysis 1.16.3 Evidence set","status":"draft","note":[{"text":"Short names for Evidence sources are detailed in \"References to studies included in this review\""}],"relatedArtifact":[{"type":"citation","label":"Wardlaw 2014","display":"Analysis 1.16.3 from Wardlaw 2014","citation":"Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2014 Jul 29(7):CD000213. PMID 25072528","url":"https://doi.org/10.1002/14651858.CD000213.pub3"}],"actual":true,"characteristicCombination":"union","characteristic":[{"definitionReference":{"type":"Evidence","display":"NINDS 1995"}},{"definitionReference":{"type":"Evidence","display":"ECASS 1995"}},{"definitionReference":{"type":"Evidence","display":"ECASS II 1998"}},{"definitionReference":{"type":"Evidence","display":"ATLANTIS B 1999"}},{"definitionReference":{"type":"Evidence","display":"ATLANTIS A 2000"}},{"definitionReference":{"type":"Evidence","display":"IST3 2012"}}],"handling":"dichotomous"}